Oxford BioDynamics (OBD) and King’s College London (KCL) have partnered to use OBD’s EpiSwitch technology to identify patients at risk of rheumatoid arthritis (RA) who can benefit from abatacept treatment.
Results from a Phase 2b clinical trial, published today in The Lancet by researchers led by King’s, provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonising chronic inflammatory d
A drug already used to alleviate some of the painful symptoms of rheumatoid arthritis might also be effective at stopping it from developing to begin with – potentially saving millions of people from this debilitating condition.
Researchers say that abatacept, a drug sold under the brand name Orencia that is used to treat rheumatoid arthritis, may also help prevent the disease in some higher risk people